Venkat Kalyan, General Manager, Novo Nordisk Gulf. Image Courtesy: Novo Nordisk
The appointment reinforces the company’s confidence in the Gulf’s evolving healthcare ecosystem
Press Release
Dubai, UAE – Novo Nordisk has appointed Mr. Venkat Kalyan as General Manager for Novo Nordisk Gulf. The appointment reinforces the company’s confidence in the Gulf’s evolving healthcare ecosystem and the UAE’s growing role as a strategic centre for medical research, innovation, and partnership-led growth.
In this role, Mr. Kalyan will oversee Novo Nordisk’s operations across the UAE, Qatar, Kuwait, Bahrain, Oman, and Yemen. He will focus on strengthening healthcare partnerships, advancing innovation, and improving outcomes for patients living with chronic diseases.
Mr. Kalyan commented: “The Gulf markets hold real potential and are exceptionally well positioned to lead the next phase of healthcare transformation. I look forward to building on Novo Nordisk’s strong foundation in the region and working closely with all our healthcare stakeholders to improve outcomes for patients.”
Mr. Kalyan brings nearly 30 years of experience in the pharmaceutical and healthcare sector, including 18 years at Novo Nordisk, most recently as General Manager of the Gulf Emerging Markets Cluster. His prior leadership experience spans across diverse markets such as India, Switzerland, Denmark, Middle Africa, South Africa and Gulf countries.
With its rapidly evolving healthcare landscape, the Gulf markets have become an integral part of Novo Nordisk’s global growth strategy, as the company renews its commitment to expanding its impact across the region and advancing accessible and sustainable patient care systems for these communities.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
© ZAWYA 2026